| Literature DB >> 31940047 |
Emilie Fowler, Gil Yosipovitch.
Abstract
For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.Entities:
Keywords: antipruritics; cytokines; pruritus; unmyelinated nerve fibers
Mesh:
Substances:
Year: 2020 PMID: 31940047 PMCID: PMC9128916 DOI: 10.2340/00015555-3347
Source DB: PubMed Journal: Acta Derm Venereol ISSN: 0001-5555 Impact factor: 3.875